Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present a corporate overview and hold virtual 1x1 meetings at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on demand starting September 12 at 7:00 am ET. Windtree focuses on late-stage interventions for acute cardiovascular disorders, particularly developing the first-in-class treatment, istaroxime, for acute heart failure. The company also has a portfolio that includes rostafuroxin for genetically targeted hypertensive patients.

AI-generated analysis. Not financial advice.

News Market Reaction – WINT

-2.34%

-2.34% News Effect

On the day this news was published, WINT declined 2.34%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARRINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24^th Annual Global Investment Conference taking place on September 12-14, 2022.

The presentation will be available on demand beginning at 7:00 am ET on Monday, September 12^th. To view the presentation or request a 1x1 meeting, click HERE to register and attend the event or contact your H.C. Wainwright representative.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com

Media contact:
Katie Larch / Robert Flamm, Ph.D.
Burns McClellan, Inc.
klarch@burnsmc.com / rflamm@burnsmc.com

FAQ

When will Windtree Therapeutics present at the H.C. Wainwright conference?

Windtree Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.

How can I view Windtree Therapeutics’ presentation?

Windtree Therapeutics' presentation will be available on demand starting at 7:00 am ET on September 12, 2022.

What is istaroxime and its significance for Windtree Therapeutics?

Istaroxime is being developed by Windtree Therapeutics as a first-in-class treatment for acute heart failure.

What is the focus of Windtree Therapeutics?

Windtree Therapeutics focuses on late-stage interventions for acute cardiovascular disorders.

What products are included in Windtree’s portfolio?

Windtree’s portfolio includes istaroxime and rostafuroxin, targeting acute heart failure and genetically defined hypertensive patients, respectively.